Bumetanide

Brand (proprietary) name

None — marketed under its generic name

Generic (nonproprietary) name

Bumetanide

Active ingredient(s)

bumetanide

Strength(s)

.25 mg/mL

Dosage form(s)

Injection; Injection, Solution

Route(s)

Intramuscular; Intravenous

Manufacturer / labeler

Hospira, Inc.Hikma Pharmaceuticals USA Inc.Sagent PharmaceuticalsCamber Pharmaceuticals, Inc.HF Acquisition Co LLC, DBA HealthFirstCardinal Health 107, LLCFresenius Kabi USA, LLCQilu Pharmaceutical Co., Ltd.Gland Pharma LimitedGLENMARK PHARMACEUTICALS INC., USALupin Pharmaceuticals, Inc.Athenex Pharmaceutical Division, LLC.Bryant Ranch PrepackNovadoz Pharmaceuticals LLCCivica, Inc.Mullan Pharmaceutical Inc.Anthea Pharma Private Limited

Product class

Generic (ANDA) (derived from FDA marketing category)

Marketing category

ANDA

Application number(s)

ANDA074332, ANDA074441, ANDA079196, ANDA215364, ANDA216434, ANDA217153, ANDA218746, ANDA219116, ANDA220427

Earliest marketing start

Jul 6, 2006

Products / packages indexed

36 / 39

FDA pharmacologic class: Increased Diuresis at Loop of Henle [PE]; Loop Diuretic [EPC]

Also searchable as: Bumetanide

Prescribing information on DailyMed (NLM)

• J1939JJ-code: Drugs administered other than oral method; chemotherapy drugsActiveDerived calculation

  Injection, bumetanide, 0.5 mg

  Derived: 24 of 39 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J1939. CMS quarters Q1 2024 – Q4 2026

  J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.

No authoritative public data was located for this field.

Which Medicare benefit pays for this drug?

• Coverage documents for bumetanide NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “bumetanide”. Covered diagnosis codes are listed in the articles.
• Coverage documents for J1939 NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “J1939”. Covered diagnosis codes are listed in the articles.

No current Medicare Billing and Coding article lists J1939.

• FDA NDC Directory data is submitted by labelers; FDA notes that inclusion does not mean the information was verified or that a product is approved, covered, or reimbursable.
• HCPCS links are derived from CMS NDC–HCPCS crosswalks, which support ASP-based Part B payment and are not a complete list of billable NDCs.
• Product class (brand, generic, biosimilar) is derived from the FDA marketing category and Purple Book license type, not from a commercial compendium.
• Payment limits are Medicare Part B national limits; they do not reflect payer contracts, OPPS rates, 340B pricing, or acquisition cost.
• Home infusion per diem S-codes are matched by therapy category from the FDA pharmacologic class and route, not from a CMS crosswalk. Payers choose which per diem codes they accept, and the right code can depend on the dosing schedule, infusion method, or daily volume.